About OxSonics
OxSonics is a company based in Oxford (United Kingdom) founded in 2013 by Christian Coviello, Constantin Coussios, and Robert Carlisle. OxSonics has raised $15.94 million across 3 funding rounds from investors including Winton, Oxford University Innovation and Longwall Ventures. The company has 14 employees as of June 30, 2024. OxSonics offers products and services including SonoTran® Platform. OxSonics operates in a competitive market with competitors including Guardant Health, GSK, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
- Headquarter Oxford, United Kingdom
- Employees 14 as on 30 Jun, 2024
- Founders Christian Coviello, Constantin Coussios, Robert Carlisle
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oxsonics Limited
- Date of Incorporation 03 Jul, 2013
- Jurisdiction OXFORD, UNITED KINGDOM
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$15.94 M (USD)
in 3 rounds
-
Latest Funding Round
$11.46 M (USD), Series B
Jan 10, 2017
-
Investors
Winton
& 2 more
-
Employee Count
14
as on Jun 30, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OxSonics
OxSonics offers a comprehensive portfolio of products and services, including SonoTran® Platform.
Enhances delivery of anti-cancer drugs into solid tumors for better efficacy.
People of OxSonics
Unlock access to complete
Funding Insights of OxSonics
OxSonics has successfully raised a total of $15.94M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $11.46 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OxSonics
OxSonics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Winton, Oxford University Innovation and Longwall Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage deeptech businesses are supported through venture capital investments.
|
Locked | Locked | Locked | |
|
Startups are incubated by Oxford University Innovation.
|
Locked | Locked | Locked | |
|
Diversified investment management is conducted by Winton globally.
|
Locked | Locked | Locked |
Investor details for OxSonics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OxSonics
Investment portfolio details for OxSonics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OxSonics
Detailed financials for OxSonics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oxsonics Comparisons
Peer comparison for OxSonics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OxSonics
OxSonics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, GSK, Denali Therapeutics, Foundation Medicine and ArcherDX, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
Detailed competitors of OxSonics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oxsonics
Complete news archive for OxSonics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OxSonics
OxSonics was founded in 2013 and raised its 1st funding round 1 year after it was founded.
OxSonics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Jérome Marzinski is the current CEO of OxSonics.
OxSonics is a funded company, having raised a total of $15.94M across 3 funding rounds to date.
As of Jun 30, 2024, the latest employee count at OxSonics is 14.
Developer of ultrasound technologies to enhance anticancer drug delivery to solid tumors. Its flagship product SonoTran is an ultrasound device designed to visualize, target, and pump therapeutic agents into tumor tissue in real-time. it also offers SonoTran Particles which are Infused alongside oncology drugs and ultrasound induces localized cavitation, improving drug penetration within tumors.
OxSonics's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
OxSonics offers SonoTran® Platform.
OxSonics has 3 investors. Key investors include Winton, Oxford University Innovation, and Longwall Ventures.